Psychiatric medication management for Boca Raton — measurement-based, in-person.

RECO Integrated Psychiatry runs full 60-to-90-minute DSM-5-TR evaluations and structures every follow-up around scored PHQ-9, GAD-7, and diagnosis-specific instruments — the standard for outpatient specialty psychiatry, not the standard for a rushed primary care refill. For Boca Raton adults, the Delray Beach office is eleven miles up Federal Highway, about twenty minutes from Mizner Park, and rTMS and Spravato are delivered on-site when oral pharmacotherapy plateaus rather than referred out.

From Mizner Park or Royal Palm Place, RECO Integrated Psychiatry’s Delray Beach office sits eleven miles north on Federal Highway — roughly a twenty-minute drive that keeps specialty outpatient psychiatry inside the rhythm of a working week rather than requiring time off or a residential program. For adults in Boca Raton whose depression, anxiety, bipolar disorder, ADHD, PTSD, or OCD has outlasted the SSRI-plus-Wellbutrin sequence a primary care office had time to try, the practical question is whether a psychiatrist will actually work the treatment algorithm through to completion. What follows describes what that looks like at RECO.

What a real psychiatric evaluation actually covers

The initial visit runs 60 to 90 minutes and ends with a written DSM-5-TR diagnostic formulation, not a symptom checklist. That distinction matters clinically: a formulation names the primary and rule-out diagnoses, identifies the temporal course, and specifies the pharmacologic class the plan will start from. It is what allows the second visit to build on the first rather than repeat it.

History-taking is granular. Prior medication trials are documented with the actual dose, duration, and specific reason for discontinuation — a patient who “didn’t tolerate sertraline” at 25 mg for four days has not had an SSRI trial. Family psychiatric history is mapped across at least two generations, substance use is screened directly rather than inferred, and trauma history is taken when the presentation, sleep architecture, or interpersonal pattern suggests it is clinically relevant. Anyone presenting with “depression” or “anxiety” is screened for bipolar-spectrum illness (MDQ), adult ADHD (ASRS), and OCD (Y-BOCS) — three diagnoses routinely missed in general practice, each of which changes the pharmacology entirely.

Baseline laboratory work is ordered where indicated: CBC, comprehensive metabolic panel, TSH with reflex to free T4, B12 and folate, and 25-hydroxy vitamin D. Untreated hypothyroidism, iron deficiency, and B12 deficiency mimic and worsen depression; ordering the labs at intake is the difference between treating an endocrine problem and layering a fourth antidepressant on top of it.

Measurement-based care and why it changes outcomes

RECO’s visits are structured around instruments. PHQ-9 for depressive symptoms, GAD-7 for generalized anxiety, PCL-5 for PTSD symptom burden, MDQ for bipolar screening at intake, ASRS for adult ADHD, and Y-BOCS for OCD severity — each completed before the visit through the patient portal, scored inside the visit, and plotted over time. The scores are not decorative. They anchor the clinical decision that follows.

The evidence base for measurement-based care is settled: multiple randomized trials and meta-analyses show meaningful improvements in remission rates when treatment adjustments are made against a scored trajectory rather than against a global “how are you feeling today.” The mechanism is straightforward. Patients under-report gains from a low baseline and under-report worsening from a high one, while clinicians pattern-match to the last visit. A tracked PHQ-9 that has moved from 19 to 14 over six weeks is a partial response that argues for augmentation, not a class switch — a decision the numbers make legible.

Follow-up cadence is tied to the scale rather than to the calendar. A patient still above threshold at week six triggers a specific next step — dose optimization, augmentation, mechanism switch, pharmacogenomic testing, or referral for interventional treatment — rather than another “let’s give it more time.”

The pharmacologic toolkit beyond the first two SSRIs

First-line pharmacotherapy is not the differentiator. Sertraline, escitalopram, venlafaxine, and duloxetine for unipolar depression and anxiety; lithium, lamotrigine, quetiapine, and lurasidone for bipolar spectrum; stimulants and atomoxetine or viloxazine for ADHD; SSRIs at anti-obsessional doses paired with an ERP referral for OCD — the guidelines are clear, and any competent prescriber can execute them. What distinguishes specialty psychiatry is what happens at step three and after.

For treatment-resistant unipolar depression, RECO’s psychiatrists work through the full sequence: optimization to the top of the therapeutic range, augmentation with aripiprazole (2 to 15 mg), lithium (target 0.6 to 0.8 mEq/L), or T3 thyroid (25 to 50 mcg); switching within class and then across mechanism; consideration of MAOIs — tranylcypromine, phenelzine — in appropriately selected patients; and pharmacogenomic panels (GeneSight, Genomind) in complex or highly medication-sensitive cases where CYP2D6 or CYP2C19 metabolism is likely relevant. Buspirone augmentation for residual anxiety, mirtazapine combination for insomnia and appetite, and low-dose atypicals are used deliberately rather than reflexively.

When the pharmacologic ceiling is reached, escalation happens on-site. RECO offers outpatient psychiatric medication management integrated with rTMS — a standard course delivers approximately 3,000 pulses per session at 120% of resting motor threshold across 36 sessions — and Spravato (esketamine) for treatment-resistant depression, so the transition from oral pharmacotherapy to interventional treatment happens without a handoff to a different practice.

Monitoring: the labs, the metabolic panel, the drug levels

Psychotropic prescribing without monitoring is a liability problem for the practice and a health problem for the patient. RECO’s protocol builds required labs into the visit cadence so nothing is contingent on the patient remembering to ask.

Lithium requires baseline TSH, creatinine, calcium, and pregnancy testing where applicable; a trough level five days after each dose change; and quarterly levels, TSH, and renal function once stable. Second-generation antipsychotics — quetiapine, olanzapine, aripiprazole, risperidone — require baseline weight, waist circumference, blood pressure, fasting glucose or HbA1c, and lipid panel, then annual reassessment and earlier if the patient gains more than 5% of body weight. Valproate requires baseline and periodic LFTs, CBC with platelets, and a 12-hour trough level. Lamotrigine requires the slow titration schedule and clear rash counseling documented in the chart.

Stimulant prescribing includes a cardiovascular history, blood pressure and heart rate at every visit, and a treatment agreement that addresses diversion risk directly. Controlled substance prescribing is checked against Florida’s PDMP (E-FORCSE) at every visit. These are unglamorous items, and they are the ones that most often go missing in less-structured settings.

What to expect on your first visit from Boca Raton

Intake paperwork and the baseline symptom battery are completed before arrival through a secure patient portal. The evaluation runs 60 to 90 minutes with a board-certified psychiatrist and ends with three deliverables: a written DSM-5-TR formulation, a medication plan with the rationale for each choice, and a follow-up cadence anchored to the target symptom score.

The first follow-up is typically at two to four weeks depending on the medication started and initial acuity. Follow-ups are 30 minutes, scored against the same instruments used at intake, and structured around the trajectory rather than a new problem list at each visit. Between visits, the practice is reachable for adverse-effect and dose questions during business hours; after-hours emergencies are triaged to the appropriate level of care.

Insurance and admissions from Boca Raton

RECO Integrated Psychiatry accepts most major commercial plans carried by Boca Raton residents — Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield — and verifies benefits before the intake so the out-of-pocket estimate is on the table before treatment begins. Self-pay rates are published on request, and Superbills are issued for out-of-network reimbursement.

The Delray Beach office is an eleven-mile, roughly twenty-minute drive up Federal Highway or I-95 from Mizner Park, Royal Palm Place, and Downtown Boca; slightly longer from Boca West via Glades Road, and slightly shorter from Highland Beach. Telepsychiatry follow-ups are available to established patients across Florida when in-person visits are impractical, though initial evaluations are conducted in person to allow direct observation of mental status.

Serving residents of: Mizner Park, Royal Palm Place, Downtown Boca, Boca West, Highland Beach.